Participated · Equity · Sep 2025

Founded in 2011 as Think and Learn Pvt. Ltd. by Byju Raveendran, BYJU'S offers interactive digital lessons and test-prep courses spanning grades 1-12 and exams such as IIT-JEE, NEET, CAT, and IAS. The company’s mobile app combines video‐based content and adaptive assessments to strengthen core concepts for more than 250 million school-age students across India. BYJU'S quickly attracted marquee global investors, helping it scale its subscription model and aggressively market its offerings. In 2018 it raised a large $540 million round that pushed its valuation to $3.6 billion, officially making it India’s first edtech unicorn. Key backers include Sequoia Capital, Tencent, Chan Zuckerberg Initiative, Sofina, Naspers Ventures, and Canada Pension Plan Investment Board. While expanding, the company has faced headwinds; in May 2024 Mumbai Police’s Economic Offences Wing filed an FIR alleging ₹46.90 crore of fraud related to student loan partnerships, naming founder-CEO Byju Raveendran and other directors. The combination of rapid growth, significant capital, and recent legal scrutiny positions BYJU'S at a critical juncture as it pursues further expansion and regulatory resolution.

Participated · Series A · May 2025

Somite.ai develops large-scale foundation models for human stem cells and a full-stack platform to accelerate discovery and optimization of cell therapies. The company’s proprietary capsule-based data generation platform produces differentiation data at approximately one‑thousandth the cost of traditional methods, enabling dense, causal datasets for training powerful predictive models. Somite combines low-cost data generation, large-scale model training, and model-driven discovery to compress development timelines for cell therapies. The company announced a collaboration with AMD Ventures to pair its platform with AMD Instinct GPUs, boosting compute for model training and exploring optimization of software tools for biological data. The founding team includes repeat AI entrepreneur Dr. Micha Breakstone, the Head of the Fundamental AI Group at MIT, and three National Academy of Science members. Somite is based in Boston, launched operations in January 2024, and has raised approximately $60M to date. Somite AI builds DeltaStem, a foundation-model platform and associated tools to design and optimize cell differentiation protocols for scalable human cell production. Its proprietary capsule technology generates cell state transition and signaling data at roughly 1,000x the efficiency of existing methods, which feeds DeltaStem. The company plans to use the platform to advance internal therapeutic programs including beta cells for type 1 diabetes, articular cartilage for orthopedic applications, satellite cells for muscular diseases, and hematopoietic cells for blood disorders. Somite positions DeltaStem as a generalizable foundation model for developmental biology, aiming to deliver protocols with improved purity, scalability, and reliability. The company reported closing a Series A financing of more than $47 million to accelerate platform development and key programs. Founders and scientific leadership include Dr. Micha Breakstone and Dr. Jonathan Rosenfeld alongside noted academic co‑founders such as Olivier Pourquié, Allon Klein, Jay Shendure, and Cliff Tabin. Somite Therapeutics builds AI foundation models (AlphaStem) that generate large datasets to design and produce human tissues for cell-replacement therapies. The company focuses on developing scalable cell therapies for diseases such as diabetes, obesity, and muscular dystrophies, and its pipeline includes SMT-M01 for Duchenne muscular dystrophy and SMT-B01 for metabolic disorders. Somite plans to use generated data to iteratively improve its platform and expand therapy creation across broader indications. The team is led by founder and CEO Dr. Micha Breakstone and includes senior scientific and translational leaders and prominent academic co-founders. Financially, Somite completed a $4.8M extension of its pre-seed round, bringing total funds raised to over $10M. The new capital is earmarked to expedite data generation for AlphaStem, advance SMT-M01 toward the clinic, initiate the SMT-B01 program, and begin research with hypoimmune cell lines. Somite is a Boston, MA–based developer of AI for stem cell biology building foundation models to produce human tissue for cell therapies. Its proprietary AlphaStem AI platform generates massive datasets that improve the platform and enable therapy creation through rapid optimization cycles. The company focuses on producing cells derived from somites — including muscle, brown adipose, cartilage, bone, tendon, and dermis — to address diseases such as diabetes, obesity, and muscular dystrophies. Somite is also pioneering a computational digital twin of the embryo that draws on scRNA-Seq, scATAC-seq, and gene expression databases to mirror development and identify regulators of cell differentiation. The team combines AI and developmental biology expertise and includes CEO and co-founder Micha Breakstone alongside scientific co-founders such as Olivier Pourquie, Allon Klein, and Cliff Tabin. The company raised funding to continue development of AlphaStem and advance its platform.

Participated · Seed · Nov 2024

Citizen Health builds a patient-centered platform that helps people interpret medical records, track symptoms, learn from peers, manage appointments, and connect to next steps in their care. The company is focused on rare and complex diseases and is developing a personalized AI Advocate intended to take initiative on behalf of patients. It has created over 60 engaged communities across 123 rare and complex conditions and partnered with 70+ patient advocacy groups, about 70% of which joined organically. The platform reports that 98.3% of patients share data for research, its data has been accepted by the FDA for regulatory submission, and it collaborates with more than 10 pharmaceutical partners. Citizen Health plans to launch the first version of its AI Advocate to select communities in Q3 and is introducing a new product for patient advocacy groups while prioritizing hiring AI engineers, product builders, and designers. The company is headquartered in San Francisco and has raised $30 million in Series A funding, bringing total funding to $44 million since its December 2023 launch. Citizen Health operates an AI-powered consumer health platform that captures patients' complete health journeys, including clinical data, genetic information, imaging, and patient-reported outcomes. Its comprehensive knowledge base enables patients to access answers based on others' experiences and gives researchers immediate access to critical information to accelerate drug development. The company says the platform is designed to support over 400 million individuals managing rare and complex conditions. Co-founders Farid Vij and Nasha Fitter drew on personal experiences as patients and caregivers to build a patient-centric product. Citizen Health announced a $14.5 million seed financing and a strategic program investment and partnership with the Chan Zuckerberg Initiative. The company plans to announce additional key partnerships and new product features in the coming months.

Participated · Series F · Oct 2024

Eruditus makes education accessible and affordable to individuals, companies, and governments through short courses, degree programs, professional certificates, and senior executive programs. It collaborates with more than 80 universities across the United States, Europe, Latin America, Southeast Asia, India, and China to deliver its offerings. The company raised $150M in a Series F to fund growth and product investment. Eruditus plans to use the proceeds to invest in AI technology to enrich the learner experience, expand its business serving governments and enterprises, and deepen investments in India and the broader APAC region. The Eruditus Group employs more than 1,750 people globally and maintains offices in Mumbai, New Delhi, Shanghai, Singapore, Palo Alto, Mexico City, New York, Boston, London, and Dubai. The company emphasizes partnerships and program expansion to increase affordability and accessibility of education worldwide. Eruditus partners with leading universities (MIT, Columbia, Harvard, Cambridge, INSEAD, Wharton, UC Berkeley, IIT, IIM and others) to offer executive courses for working professionals. The firm has launched more than 100 courses in multiple languages and says it has educated over 250,000 individuals across more than 80 countries. Eruditus claims $185 million in revenue for FY21 and reported 120% year-on-year growth, estimating gross bookings of $500 million for FY22. The company is SoftBank-backed and led by Chaitanya Kalipatnapu and Ashwin Damera. Eruditus has pursued inorganic expansion, including a $200 million acquisition of Silicon Valley-based iD Tech to enter the K12 space. Management expects acquisitions to contribute up to 30% of top line and EBITDA over the next five years. Eruditus partners with over 30 top-tier universities, including MIT, Harvard, Columbia, Cambridge, INSEAD, Wharton, UC Berkeley, IIT, IIM and NUS, to develop and deliver executive-level courses. The company offers more than 100 courses priced between $5,000 and $40,000 and serves students in over 80 nations. It uses technology and data to create and deliver high-quality courses and focuses on upskilling amid rapid technological disruption. Eruditus plans to deploy the new funds to develop more courses and build new products. Financially, the ten-year-old Mumbai-based startup was valued at $3.2 billion in this round, up from about $700 million a year ago. The company counts Chan Zuckerberg Initiative and Sequoia Capital India among its existing backers. Eruditus partners with more than 30 top-tier universities to develop and deliver over 100 executive-level courses to students in over 80 nations. Course prices range from $5,000 to $40,000, and the company offers tailored learning and tracks course outcomes for learners. The Mumbai-based, 10-year-old company has offices in six countries, employs more than 650 people, and enrolled 50,000 students in the past 12 months. Partner universities named in coverage include MIT, Harvard, Columbia, Cambridge, INSEAD, Wharton, UC Berkeley, IIT, IIM and NUS. Eruditus raised new capital to further scale its business and reach more learners. It plans to use the funds to partner with more universities, expand in emerging markets, and invest in developing career-ready courses to address workforce needs. Eruditus is an Indian online education startup focused on offering online education. The company has raised $40 million in a Series C round. The round was led by Sequoia India and joined by existing investor Bertelsmann India Investments, according to the announcement. The article did not disclose product details, future plans, revenue, user metrics, or valuation. No other participating investors or financing terms were provided in the coverage.

Participated · Series F · Oct 2024

Eruditus announced it has raised $150 million in a Series F financing. The raise was reported from Kolkata on Oct. 18. The round was led by TPG’s The Rise Fund, the multi-sector strategy of TPG’s global impact investing platform. Existing investors SoftBank Vision Fund 2, Leeds Illuminate, Accel, CPP Investments and the Chan Zuckerberg Initiative participated. The article does not provide details on Eruditus’s core product, business model, future plans, or operating metrics. The report also does not disclose use of proceeds or other financial performance metrics.